OnKure Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2026 | 2025 | |
| (in thousands) | ||
| Cash flows from operating activities: | ||
| Net loss | $(48,349) | $(46,014) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 9,321 | 8,614 |
| Depreciation and amortization | 244 | 343 |
| Amortization of right-of-use asset - operating | 379 | 285 |
| Loss on disposal of property and equipment | — | 2 |
| Accretion of discount on marketable securities, net | (88) | — |
| Change in operating assets and liabilities: | ||
| Prepaid and other assets | (635) | 1,052 |
| Accounts payable, accrued and other liabilities | 3,166 | (4,240) |
| Lease liabilities | (412) | (398) |
| Other long-term liabilities | — | 40 |
| Net cash used in operating activities | (36,374) | (40,316) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (12,804) | — |
| Maturities of marketable securities | 1,000 | — |
| Purchases of property and equipment | (40) | (37) |
| Net cash used in investing activities | (11,844) | (37) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of Class A Common Stock and pre-funded warrants in connection with 2026 Private Placement | 149,999 | — |
| Payment of issuance costs associated with the 2026 Private Placement | (9,591) | — |
| Proceeds from sale of stock under the employee stock purchase plan | 203 | — |
| Payment of issuance costs associated with the Concurrent Financing | — | (37) |
| Payment of reverse recapitalization transaction costs | — | (40) |
| Net cash provided by (used in) financing activities | 140,611 | (77) |
| Net increase (decrease) in cash and cash equivalents | 92,393 | (40,430) |
| Cash and cash equivalents, beginning of period | 59,050 | 110,761 |
| Cash and cash equivalents, end of period | $151,443 | $70,331 |
| Supplemental disclosure of noncash financing activities: | ||
| Purchases of property and equipment in accounts payable | $— | $3 |
| Leased assets obtained in exchange for operating lease liabilities, upon extension | $653 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.